Streetbeat News

MGX

Metagenomi Inc.

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

1.85

Mkt cap

65M

Volume

562K

High

1.94

P/E Ratio

-0.73

52-wk high

11.86

Low

1.69

Div yield

N/A

52-wk low

1.61

Metagenomi presented promising results for Hemophilia A treatment at the ASH 66th Annual Meeting, showing sustained FVIII activity in a nonhuman primate study for over 16 months. This update is part of their 2024 financial results announcement.

Portfolio Pulse from

March 18, 2025 | 11:30 am

Metagenomi presented promising results for Hemophilia A treatment at the ASH 66th Annual Meeting, showing sustained Factor VIII activity in a nonhuman primate study for over 16 months.

Portfolio Pulse from

March 17, 2025 | 8:15 pm

Metagenomi, Inc. has published a study in Nature Communications detailing its novel CRISPR-associated transposase (CAST) system for large gene integration into human cells. This advancement could simplify delivery for therapeutic applications, with further updates expected in 2025.

Portfolio Pulse from

March 13, 2025 | 10:30 am

Metagenomi, Inc. (Nasdaq: MGX) has announced significant progress in its therapeutic portfolio, including advancements in MGX-001 for Hemophilia A and anticipated milestones for 2025. The company is on track for regulatory interactions and development candidate nominations, with a cash runway supporting operations into 2027.

Portfolio Pulse from

January 16, 2025 | 2:15 pm

Levi & Korsinsky has announced a class action lawsuit against Metagenomi, Inc. (NASDAQ:MGX) with a lead plaintiff deadline of November 25, 2024. Investors who suffered losses are encouraged to seek potential recovery under federal securities laws.

Portfolio Pulse from

November 26, 2024 | 12:45 am

Levi & Korsinsky has filed a securities class action lawsuit on behalf of Metagenomi, Inc. (NASDAQ:MGX) shareholders. Investors who suffered losses can seek potential recovery under federal securities laws.

Portfolio Pulse from

November 25, 2024 | 11:30 pm

Pomerantz Law Firm has filed a class action lawsuit against Metagenomi, Inc. (NASDAQ: MGX). Investors are encouraged to contact the firm for more information.

Portfolio Pulse from

November 25, 2024 | 11:00 pm

Levi & Korsinsky has notified investors of Metagenomi, Inc. (NASDAQ:MGX) about a class action lawsuit. Investors who suffered losses can seek potential recovery under federal securities laws.

Portfolio Pulse from

November 25, 2024 | 9:45 pm

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Metagenomi, Inc. (NASDAQ: MGX) and certain officers, offering investors with substantial losses the opportunity to lead the lawsuit.

Portfolio Pulse from

November 25, 2024 | 9:15 pm

Metagenomi, Inc. (NASDAQ:MGX) is facing a lawsuit for securities law violations. Investors who suffered losses are encouraged to contact Levi & Korsinsky before November 25, 2024, to discuss potential recovery options.

Portfolio Pulse from

November 25, 2024 | 8:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.